Signals via API

Public sample from today's flagship detail endpoint. Public payloads can be limited or redacted. The backend exposes read endpoints for signals, storylines, and briefings.

GET /v1/narratives/5ea7aa70-0321-4d05-99f7-5b373450959a?tenant=biotech

{
  "id": "5ea7aa70-0321-4d05-99f7-5b373450959a",
  "title": "GSK hails 'unprecedented' cure rates with hep B drug",
  "summary": "GSK hails 'unprecedented' cure rates with hep B drug Phil.Taylor Thu, 28/05/2026 - 11:55",
  "first_seen_at": "2026-05-28T08:39:52.638600Z",
  "last_seen_at": "2026-05-28T16:01:00Z",
  "created_at": "2026-05-28T17:08:26.922852Z",
  "updated_at": "2026-05-29T05:11:19.002374Z",
  "timeframe": "24h",
  "run_id": "0ebb6a78-9955-41a0-83c0-99cdf57884a3",
  "metrics": {
    "divergence": 15.8114,
    "post_count": 3,
    "momentum_1h": 0,
    "momentum_7d": 3,
    "score_total": 1.305916,
    "shill_score": 10,
    "momentum_24h": 3,
    "market_movers": [],
    "evidence_score": 0.75,
    "unique_authors": 3,
    "coherence_score": 0.8248,
    "diversity_bonus": 0.1625,
    "duplicate_ratio": 0,
    "platforms_count": 1,
    "social_momentum": 3,
    "divergence_label": "chatter_without_pricing",
    "market_conviction": 0,
    "origin_share_top1": 0.333333,
    "unique_publishers": 3,
    "origin_layer_posts": 0,
    "source_types_count": 1,
    "unique_authors_24h": 3,
    "unique_origin_urls": 3,
    "amplifier_share_top1": 0.333333,
    "author_concentration": 0.3333,
    "publisher_share_top1": 0.333333,
    "amplifier_layer_posts": 3,
    "concentration_penalty": 0,
    "unique_origin_domains": 3,
    "source_diversity_bonus": 0,
    "unique_publisher_types": 1,
    "unique_origin_publishers": 3
  },
  "platforms": [
    "rss"
  ],
  "top_tickers": [],
  "why_now": [],
  "display_title": "GSK’s hepatitis B drug achieves functional cure in nearly one-fifth of patients in phase 3 trials",
  "display_summary": "GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.",
  "narrative_frame_display": null,
  "entities": {
    "projects": [
      "bepirovirsen"
    ],
    "companies": [
      "GSK",
      "Ionis Pharmaceuticals"
    ]
  },
  "recurring_claims": [
    {
      "claim": "Bepirovirsen achieved functional cure in nearly 20% of patients in phase 3 trials.",
      "evidence_urls": [
        "https://biopharmadive.com/news/gsk-ionis-bepirovirsen-hepatitis-b-nejm-study-results/821341",
        "https://fiercebiotech.com/biotech/gsks-hepatitis-b-drug-cures-one-fifth-patients-major-step-pervasive-disease",
        "https://pharmaphorum.com/news/gsk-hails-unprecedented-cure-rates-hep-b-drug"
      ]
    }
  ],
  "stance_map": [
    {
      "stance": "promotes",
      "who": "BioPharma Dive",
      "evidence_urls": [
        "https://biopharmadive.com/news/gsk-ionis-bepirovirsen-hepatitis-b-nejm-study-results/821341"
      ]
    }
  ],
  "quality_flags": {
    "mixed_topic_risk": "low",
    "promo_risk": "low",
    "source_quality": "high"
  },
  "editor_note": "Consolidated multiple reports to highlight the clinical significance of bepirovirsen's phase 3 results.",
  "display_tags": [
    "clinical_trials",
    "drug_development",
    "safety_signals"
  ],
  "tags": [
    "clinical_trials",
    "drug_development",
    "safety_signals"
  ],
  "cscope_tags": [
    "clinical_trials",
    "drug_development",
    "safety_signals"
  ],
  "why_now_display": [
    "Phase 3 trial results have just been released, confirming efficacy in a large patient population.",
    "The data represent a major advancement in a field with few effective cures.",
    "GSK and Ionis are positioned to potentially bring a first-in-class hepatitis B cure to market."
  ],
  "why_it_matters_display": [
    "Hepatitis B affects millions globally with limited curative treatments.",
    "A functional cure could greatly reduce disease burden and improve outcomes.",
    "Positive phase 3 data may speed regulatory approval and treatment availability."
  ],
  "show_why": true,
  "sources_display": [
    {
      "label": "biopharmadive.com: BioPharma Dive"
    },
    {
      "label": "pharmaphorum: GSK hails 'unprecedented' cure rates with hep B drug"
    },
    {
      "label": "Fierce Biotech: GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients ..."
    }
  ],
  "trend_status": "flat",
  "trend_sparkline": "▁▁",
  "trend_points_n": 0,
  "trend_window": {
    "lookback_days": 14,
    "max_points": 36,
    "value_key": null
  },
  "llm_status": "accepted",
  "llm_meta": {
    "model": "gpt-4.1-mini-2025-04-14",
    "prompt_version": "enrich_v3",
    "input_hash": "6843b1e765a764cd69603607f910f88890d861dd14a2cac6c0decfac7f715ea2",
    "updated_at": "2026-05-29T05:14:51.496794+00:00",
    "llm_metadata": {
      "env": "prod",
      "host": "9f6818581256",
      "stage": "signals.enrich",
      "run_id": "0ebb6a78-9955-41a0-83c0-99cdf57884a3",
      "tenant": "biotech",
      "service": "api",
      "pipeline": "pipeline_run",
      "correlation_id": "5ea7aa70-0321-4d05-99f7-5b373450959a"
    }
  },
  "story_id": "5ea51017-8044-407b-b34d-b8500c3bdf4f",
  "public_surface": {
    "eligible_for_flagship_sample": true,
    "eligible_for_top_public_brief": true,
    "eligible_for_public_index": false,
    "eligible_only_for_lower_or_internal_surfaces": false,
    "public_rank_score": 12,
    "structural_priority": true,
    "mostly_social": false,
    "community_chatter": false,
    "reader_label": null,
    "excluded_reasons": [],
    "source_signals": {
      "post_count": 3,
      "unique_origins": 3,
      "source_types_count": 1,
      "independent_non_social_count": 3,
      "social_source_count": 0,
      "non_social_source_count": 0,
      "why_now_count": 3,
      "why_it_matters_count": 3
    }
  },
  "current_cycle_open": false
}

• Signals and storylines feed endpoints with filtering and rate limits
• Briefing delivery endpoints for integrations
• Evidence link payloads for auditability

• Route top stories into Slack or Teams for morning and evening desk updates.
• Sync storyline evidence into Notion, Airtable, or internal research trackers.
• Feed metrics into BI dashboards for momentum, concentration, and source mix monitoring.

Quick start endpoints: /v1/feed/stories, /v1/signals, /v1/storylines/search, /v1/briefings/latest.

For product access, see Pricing.